SARS-CoV-2 Infection and Candidate Biomarkers

Derleme MakaleAçık ErişimScopus SJRQ3
  • SDG 3 · Sağlık ve Kaliteli Yaşam

Özet

Severe acute respiratory syndrome coronavirus 2 is a virus that can still infect individuals and whose deadly effects continue despite the current vaccines and drugs. Since 2019, many studies on the pathogenesis of the disease have been completed and continue to be done. In addition to the diagnosis and treatment of the disease, many molecules that can be markers of the disease have been investigated. In the early stages of the pandemic, many nonspecific and infection-related laboratory findings and chest computed tomography were used to obtain information about the diagnosis of the disease. The more individual molecules became associated with the disease yet. The purpose of this review is to summarize the impact and role of many molecules associated with coronavirus disease-2019 infection that have been previously used and newly revealed. Numerous studies are summarized in this review. The obtained data show that previously used laboratory findings and new potential biomarkers are not specific to the disease. New potential biomark-ers have been associated with the severity of the disease itself, as can be seen with lung imaging and even with routine laboratory findings. One of the important points that are seen frequently in studies is that the effectiveness of these molecules has been shown not only in coronavirus disease-2019 infection but also in many other diseases. This removes the pathogenesis of the disease from being a unique mechanism created by the Severe acute respiratory syndrome coronavirus 2 and provides a general perspective formed by viral or bacterial infections. However, there are still many molecular changes that need to be investigated. Future studies will continue to update themselves with the mutations of the virus.

Anahtar Kelimeler

RDL Kalıcı Bağlantı (PID)
https://rdlopen.rawdatalibrary.net/r/bayburt/12931Resmi atıflarda kullanılan kalıcı adres
İndeks kayıtları
Kaydın indeks veri tabanlarındaki sayfası (aktarımda alınan kayıt numarasıyla). Erişim, indeksin kendi koşullarına bağlıdır.
Atıflar
Scopus
1
WoS
1
OpenAlex
0
TR Dizin
0
Her kaynağın kendi saydığı toplam atıf; aktarım ve zenginleştirme sırasında alındı.
Tam Kayıt
AlanDeğerDil
dc.contributor.authorUzunçakmak, Sevgi Karabulut
dc.date.accessioned2026-10-29T19:10:14.875300570Z
dc.date.available2026-10-29T19:10:14.875300570Z
dc.date.issued2022
dc.description.abstractSevere acute respiratory syndrome coronavirus 2 is a virus that can still infect individuals and whose deadly effects continue despite the current vaccines and drugs. Since 2019, many studies on the pathogenesis of the disease have been completed and continue to be done. In addition to the diagnosis and treatment of the disease, many molecules that can be markers of the disease have been investigated. In the early stages of the pandemic, many nonspecific and infection-related laboratory findings and chest computed tomography were used to obtain information about the diagnosis of the disease. The more individual molecules became associated with the disease yet. The purpose of this review is to summarize the impact and role of many molecules associated with coronavirus disease-2019 infection that have been previously used and newly revealed. Numerous studies are summarized in this review. The obtained data show that previously used laboratory findings and new potential biomarkers are not specific to the disease. New potential biomark-ers have been associated with the severity of the disease itself, as can be seen with lung imaging and even with routine laboratory findings. One of the important points that are seen frequently in studies is that the effectiveness of these molecules has been shown not only in coronavirus disease-2019 infection but also in many other diseases. This removes the pathogenesis of the disease from being a unique mechanism created by the Severe acute respiratory syndrome coronavirus 2 and provides a general perspective formed by viral or bacterial infections. However, there are still many molecular changes that need to be investigated. Future studies will continue to update themselves with the mutations of the virus.
dc.identifier.doi10.5152/eurasianjmed.2022.22305
dc.identifier.eissn1308-8742
dc.identifier.endpageS22
dc.identifier.issn1308-8734
dc.identifier.issue1
dc.identifier.pmcidPMC11163343
dc.identifier.pmid36655440
dc.identifier.scopus2-s2.0-85146358564
dc.identifier.startpageS16
dc.identifier.urihttps://rdlopen.rawdatalibrary.net/r/bayburt/12931
dc.identifier.volume54
dc.identifier.wosWOS:000926902700003
dc.language.isoen
dc.publisherAVES
dc.relation.ispartofEurasian Journal of Medicine
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectbiomarkers
dc.subjectCOVID-19
dc.subjectinfectious disease
dc.subjectSARS-CoV-2
dc.subject.classificationMedicine, General & Internal
dc.subject.classificationGeneral & Internal Medicine
dc.subject.otherTISSUE GROWTH-FACTOR
dc.subject.otherVITAMIN-D LEVELS
dc.subject.otherCOVID-19 PATIENTS
dc.subject.otherCLINICAL-COURSE
dc.subject.otherRECEPTOR SUPAR
dc.subject.otherPROGRANULIN
dc.subject.otherTHROMBOCYTOPENIA
dc.subject.otherFIBRONECTIN
dc.subject.otherMOLECULE-1
dc.subject.otherIMMUNITY
dc.titleSARS-CoV-2 Infection and Candidate Biomarkers
dc.typeReview Article
rdl.citation.openalex0
rdl.citation.scopus1
rdl.citation.trdizin0
rdl.citation.wos1
rdl.departmentHealth Services Vocational School, Bayburt University, Bayburt, Turkey
rdl.oa.statusgold
rdl.oa.statusgreen
rdl.oa.urlhttps://doi.org/10.5152/eurasianjmed.2022.22305
rdl.scopus.quartileQ3
rdl.sdgSDG03
rdl.source.indexSCOPUS
rdl.source.indexWOS
rdl.source.indexTRDIZIN
rdl.source.indexPUBMED
rdl.wos.indexEmerging Sources Citation Index (ESCI)